Gastric Ulcers Market
Report ID: SQMIG35I3454
Report ID: SQMIG35I3454
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3454 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
174
|Figures:
79
Global Gastric Ulcers Market size was valued at USD 6.87 Billion in 2024 and is poised to grow from USD 7.41 Billion in 2025 to USD 13.51 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).
The global gastric ulcer market trends includes pharmaceuticals, diagnostics, and endoscopic devices for treatment and management of peptic lesions in the lining of the stomach. The reason for studying it is because ulcer disease is very common and affects up to 10% of the adult population throughout the world and has costs for health care. The increasing incidence of Helicobacter pylori infection and increasing use of non-steroidal anti-inflammatory drugs that directly damage the gastric mucosa have been the major factors driving the market growth. The past decade has seen an upsurge in product launches driven by the regulatory approvals of proton-pump inhibitors and the use of urease tests, demonstrating how unmet needs translate into commercial growth.
The key trend that will impact the global gastric ulcer market growth is the convergence of demographic trends and diagnostics which together unleash demand and sources of income. The regulatory momentum will be built on furthering the trend. Older populations have higher rates of comorbid conditions such as cardiovascular disease and therefore have increased exposure to NSAIDs and thus increased ulcer incidence, and gastro‑protective agents are often prescribed by clinicians. In the meantime, the introduction of H. pylori testing kits in developing countries shortens the time until diagnosis, so that treatment can be started earlier and the pool of patients can be enlarged. Demographic pressure and innovative delivery create opportunities for growth, as illustrated by companies that are introducing tele‑medicine platforms with prescription monitoring and gaining market share.
How is AI Improving Diagnosis and Treatment Outcomes in the Gastric Ulcers Market?
Artificial intelligence is transforming the gastric ulcers market share by enabling faster diagnosis, improving treatment accuracy, and supporting personalized patient management. AI-powered image analysis integrated with endoscopy systems can detect subtle gastric mucosal abnormalities, early ulcerative lesions, and bleeding sites with high precision, reducing the likelihood of missed diagnoses while assisting gastroenterologists in real-time clinical decision-making. Machine learning algorithms are also being used to analyze patient history, medication usage, Helicobacter pylori infection status, and lifestyle factors to predict ulcer risk and recommend individualized treatment strategies.
In addition, AI-driven clinical decision support systems help optimize proton pump inhibitor therapy, monitor patient adherence, and identify individuals at greater risk of ulcer recurrence or complications. The integration of AI with telehealth platforms and electronic health records further enhances remote monitoring, follow-up care, and timely intervention, improving treatment outcomes while reducing healthcare costs. As healthcare providers increasingly adopt AI-enabled diagnostic and predictive technologies, these innovations are expected to enhance clinical efficiency, expand access to early diagnosis, and drive sustained growth in the global gastric ulcers market.
Market snapshot - (2026-2033)
Global Market Size
USD 6.87 Billion
Largest Segment
Copper Indium Gallium Selenide Targets
Fastest Growth
Cadmium Selenide Targets
Growth Rate
7.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global gastric ulcers market is segmented by drug class, disease type, route of administration, distribution channel, end user, and region. Based on by drug class, the market is segmented into proton pump inhibitors (PPIs), H2 receptor antagonists, antibiotics (for helicobacter pylori eradication), antacids, cytoprotective agents, and others. Based on by disease type, the market is segmented into gastric ulcers, duodenal ulcers, stress ulcers, and peptic ulcers. Based on by route of administration, the market is segmented into oral and injectable. Based on by distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on by end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and home care settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Proton Pump Inhibitors (PPIs) dominate the gastric ulcers market because they are the first-line therapy for reducing gastric acid secretion and promoting ulcer healing. Their superior efficacy in relieving symptoms, preventing ulcer recurrence, and supporting Helicobacter pylori eradication regimens has made them the preferred treatment across hospitals, specialty clinics, and outpatient settings. The widespread availability of branded and generic formulations, favorable clinical outcomes, and strong recommendations in treatment guidelines continue to reinforce the segment's leading market position.
Antibiotics represent the fastest-growing segment as increasing diagnosis of Helicobacter pylori infection and growing adoption of combination eradication therapies continue to drive demand. Rising awareness of infection-related ulcers, improving diagnostic capabilities, and the development of optimized antimicrobial regimens are further supporting the rapid expansion of this segment.
The oral administration segment dominates the market because most gastric ulcer medications, including PPIs, H2 receptor antagonists, antacids, and antibiotics, are available as tablets, capsules, or suspensions that offer convenient self-administration and high patient compliance. Oral formulations reduce the need for hospitalization, lower treatment costs, and are well suited for both short-term symptom relief and long-term maintenance therapy, making them the preferred choice among healthcare providers and patients.
The injectable administration segment is expected to witness the fastest growth due to increasing use in hospitalized and critically ill patients who cannot tolerate oral medications or require rapid acid suppression. The growing incidence of stress ulcers in intensive care units, expanding emergency care services, and the availability of intravenous PPIs are contributing to the segment's accelerated growth.
To get detailed segments analysis, Request a Free Sample Report
The North America’s gastric ulcers market is driven by a combination of advanced healthcare infrastructure, high physician awareness and good reimbursement mechanisms that provides wide access to diagnostic and therapeutic innovations by the patients. The United States has leading academic medical centers and a strong pipeline of pharmaceutical research, while Canada’s publicly funded system emphasizes equal access to care and early intervention. The region benefits from the strength of integrated specialist networks, a high level of adoption of minimally invasive endoscopic techniques and industry and clinical partnerships that sustain a deep and sophisticated treatment and market.
Gastric ulcers market outlook in the United States benefits from a sophisticated healthcare delivery network, leading academic centers, and a culture of early diagnosis. The presence of major pharmaceutical firms fosters continual pipeline innovation, while insurance frameworks support broad patient access to advanced therapies. Nationwide collaborative research consortia and high adoption of minimally invasive procedures further reinforce market depth, ensuring that treatment standards remain at the forefront of clinical practice.
Gastric ulcers market forecast in Canada is supported by a publicly funded health system that emphasizes equitable access to diagnostic endoscopy and evidence‑based pharmacotherapy. Strong provincial research initiatives encourage clinical trials that align with international guidelines. Integration of multidisciplinary gastroenterology teams promotes comprehensive patient management, while a growing emphasis on patient education improves early detection. These systemic strengths collectively create a robust nationally stable environment for continued sustained market activity.
Europe’s rapid growth is fuelled by harmonized regulations, robust clinical research networks, and increased awareness among clinicians and patients. Comprehensive health care systems emphasize early detection through regular endoscopic screening and reimbursement systems are increasingly incorporating advanced therapeutic agents. In addition, collaboration between academic institutions, biotech companies, and public health agencies encourages ongoing innovation, especially in the area of biologic and peptide-based therapies. Demographic trends, such as an aging population and lifestyle-related risk factors, generate ongoing demand for effective management solutions. These factors combine to make Europe a key battleground for both market growth and introduction of next-generation ulcer therapies.
Gastric ulcers market regional outlook in Germany is anchored by a highly organized health‑care delivery system that emphasizes guideline‑driven treatment pathways. Robust funding for gastroenterology research sustains a pipeline of novel therapeutic candidates, while leading university hospitals provide early access to cutting‑edge interventions. Strong collaboration between pharmaceutical firms and regulatory agencies accelerates product approval, and comprehensive insurance coverage ensures widespread patient uptake. These factors collectively reinforce Germany’s dominant position within the European landscape.
Gastric ulcers market regional forecast in the United Kingdom is driven by a blend of public and private health‑care that emphasizes rapid diagnosis and evidence‑based therapy. The National Health Service supports broad endoscopic screening, while private clinics adopt innovative drug formulations. Investment in translational research hubs speeds development of targeted treatments, and collaborative trial networks enable swift patient enrollment. This environment reinforces the United Kingdom’s position as the fastest‑growing market in Europe.
Gastric ulcers market analysis in France is emerging as healthcare stakeholders place greater emphasis on preventative gastroenterology and patient education. National health insurance increasingly reimburses endoscopic procedures and novel pharmacologic agents, encouraging broader clinical adoption. Research collaborations between university hospitals and biotech firms stimulate incremental advances in mucosal healing therapies. Growing awareness of lifestyle risk factors drives demand for early intervention, positioning France as a promising growth frontier within the continental market.
Asia Pacific is steadily strengthening its position in the gastric ulcers market, driven by a combination of advanced medical technology adoption, expanding health-care financing, and targeted research initiatives. Japan has a long history of endoscopic expertise and a culture of early intervention, and South Korea is focused on fast regulatory pathways to quickly get innovative therapies to patients. Both economies are benefiting from rising awareness of gastro-intestinal health and a higher prevalence of risk factors linked to dietary changes. Clinical development pipelines are accelerated by collaborative networks connecting academic centers, contract research organizations, and multinational manufacturers. Together, these dynamics enhance the region’s ability to provide quality ulcer management solutions and reinforce its role as a more significant market contributor.
Gastric ulcers market penetration in Japan is characterized by a sophisticated endoscopic infrastructure and a strong emphasis on preventive screening. Universal health coverage ensures widespread access to diagnostic procedures, while pharmaceutical innovation thrives within integrated research institutions. Collaborative efforts between leading universities and industry accelerate the introduction of novel acid‑suppression agents. Patient adherence programs and education campaigns further support effective disease management, reinforcing Japan’s role as a benchmark for high‑quality ulcer care.
Gastric ulcers industry in South Korea benefits from regulatory pathways that accelerate new therapies. Strong gastroenterology research within university hospitals fuels therapeutic advances. Nationwide insurance provides coverage for endoscopic diagnostics and modern drug regimens, ensuring patient access. Partnerships between domestic biotech firms and pharmaceutical companies facilitate technology transfer, while public health campaigns increase awareness of ulcer risk factors. These components collectively drive South Korea’s expanding role in the regional market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Prevalence Of H Pylori
Advancements In Endoscopic Treatment Techniques
Rising Antibiotic Resistance Concerns
Stringent Regulatory Approval Processes
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the global gastric ulcers market is shaped by major pharmaceutical players such as Daewoong Pharmaceutical, Takeda Pharmaceutical, and Pfizer, which are intensifying rivalry through strategic collaborations and advanced drug development pipelines. Recent M&A activity includes Takeda’s acquisition of niche ulcer‑treatment assets, while Daewoong has entered a partnership with a biotech firm to integrate AI‑driven diagnostics, accelerating market entry of innovative therapies.
Top Player’s Company Profile
Recent Developments in the Gastric Ulcers Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the global gastric ulcers market is propelled primarily by the rising prevalence of Helicobacter pylori infection, which fuels demand for targeted therapies, while advancements in endoscopic treatment techniques serve as a second strong catalyst by enabling minimally invasive, faster‑recovery procedures. The market’s growth is tempered by rising antibiotic‑resistance concerns that complicate treatment regimens and slow adoption of standard drugs. North America dominates the landscape, thanks to its advanced healthcare infrastructure and strong reimbursement models. Within the product mix, zinc selenide targets lead as the dominant segment, offering chemical stability that underpins high‑quality ulcer medication manufacturing globally.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 6.87 Billion |
| Market size value in 2033 | USD 13.51 Billion |
| Growth Rate | 7.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Gastric Ulcers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Gastric Ulcers Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Gastric Ulcers Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Gastric Ulcers Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Gastric Ulcers Market size was valued at USD 6.87 Billion in 2024 and is poised to grow from USD 7.41 Billion in 2025 to USD 13.51 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).
The competitive landscape of the global gastric ulcers market is shaped by major pharmaceutical players such as Daewoong Pharmaceutical, Takeda Pharmaceutical, and Pfizer, which are intensifying rivalry through strategic collaborations and advanced drug development pipelines. Recent M&A activity includes Takeda’s acquisition of niche ulcer‑treatment assets, while Daewoong has entered a partnership with a biotech firm to integrate AI‑driven diagnostics, accelerating market entry of innovative therapies. 'JX Advanced Metals Corporation', 'Tosoh Corporation', 'Materion Corporation', 'Furuya Metal Co., Ltd.', 'Kojundo Chemical Laboratory Co., Ltd.', 'Umicore SA', 'Vital Materials Co., Limited', 'Ningxia Orient Tantalum Industry Co., Ltd.', 'GRINM Advanced Materials Co., Ltd.', 'Stanford Advanced Materials', 'ALB Materials Inc.', 'Heeger Materials Inc.', 'Testbourne Ltd.', 'Kurt J. Lesker Company', 'MSE Supplies LLC', 'Advanced Engineering Materials Limited', 'EVOCHEM Advanced Materials GmbH', 'Plasmaterials, Inc.', 'American Elements Corporation', 'QS Advanced Materials Inc.'
The growing prevalence of Helicobacter pylori infection across diverse age groups raises clinical awareness and prompts early diagnostic testing, which in turn expands the demand for targeted ulcer therapies and supports ongoing product innovation within the global gastric ulcers market, fostering sustained revenue growth as healthcare providers prioritize effective eradication protocols and symptom management for affected patients. Additionally, heightened public health initiatives emphasize prevention and lifestyle modification, encouraging physicians to adopt comprehensive treatment plans that incorporate both antimicrobial and acid‑suppressive agents, thereby broadening therapeutic options and reinforcing market expansion.
Minimally Invasive Endoscopic Therapies: Growing acceptance of minimally invasive endoscopic therapies is reshaping treatment pathways for gastric ulcers, as clinicians prioritize procedures that reduce hospital stays and procedural trauma. Advanced imaging and flexible instrument designs enable targeted ulcer ablation and hemostasis, appealing to both patients and providers seeking quicker recoveries. This shift is fostering partnerships between device manufacturers and gastroenterology centers, accelerating product launches and driving demand for next‑generation therapeutic platforms that promise enhanced safety and efficacy without the need for open surgery conventional.
Why does North America Dominate the Global Gastric Ulcers Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
